Immune checkpoint immunotherapy employs monoclonal antibodies to target immune checkpoint molecules such as PD‐1 and CTLA‐4 on T‐cells and their ligands PD‐L1 and B7‐H3 on tumor cells, restoring T‐cell anticancer activity.36, 68. Here, CTLA4 is linked to neoplasm.